DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Lencioni R, Raoul J-L, Park JW, Baudelet C, Walters I.
Comparison of tumor responses by modified WHO and new RECIST criteria from a phase II study of first-line brivanib in hepatocellular carcinoma (HCC).
J Clin Oncol [Internet]. Available at:
http://meetinglibrary.asco.org/content/1758-72 . Accessed May 3, 2017
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.